Novartis AG

Swiss Stock Exchange:NOVN.SW

Sector

🏥 Health Care

Industries

💊 Pharmaceuticals

🧬 Biotechnology

🔬 Clinical Trials

Location

Switzerland

Market Cap

USD 233.61 B

Share Price

USD 117.76

Avg Daily Volume

4,098,771

Change (1 day)

-0.47%

Change (1 year)

9.97%

Change (YTD)

20.06%

Novartis AG Share Price on June 25, 2025: USD 117.76

Novartis AG Share Price is USD 117.76 on June 25, 2025, a 9.97% change year over year. Share price reflects current trading price of a company's stock; influenced by market dynamics and company performance.

Novartis AG 52-week low Share Price is USD 120.97 on June 25, 2025, which is 2.73% above the current Share Price.
Novartis AG 52-week low Share Price is USD 96.55 on June 25, 2025, which is -18.01% below the current Share Price.
Novartis AG average Share Price for the last 52 weeks is USD 109.71.

Daily

From:

To:

Zoom:

Key data

Date	Share Price	Share Price	Price to Earnings Ratio (P/E)	Price to Book Ratio (P/B)

Swiss Stock Exchange: NOVN.SW

Novartis AG

CEO	Dr. Vasant Narasimhan M.D.
IPO Date	Aug. 3, 1995
Location	Switzerland
Headquarters	Lichtstrasse 35
Employees	75,883
Sector	🏥 Health Care
Industries Pharmaceuticals 🧬 Biotechnology 🔬 Clinical Trials

Description

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.